- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07939529
People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effectiveness (PALACE)
This pilot, single-arm, open-label study conducted in the United States will evaluate the efficacy, safety, tolerability, and pharmacokinetics of long-acting lenacapavir plus cabotegravir (LA LEN+CAB) in people with HIV-1 viremia who have a history of non-adherence and confirmed or suspected rilpivirine (RPV) resistance. Participants will be on study for up to 108 weeks.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35222
- Alabama (Site ID: 31788)
-
Kontakt:
- Heather Logan
- Telefonnummer: 205-934-6774
- E-Mail: heatherlogan@uabmc.edu
-
-
California
-
Los Angeles, California, Vereinigte Staaten, 90035
- University of California, Los Angeles CARE Center (Site ID: 601)
-
Kontakt:
- Aleen Khodabakhshian
- Telefonnummer: 310-557-3798
- E-Mail: akhodabakhshian@mednet.ucla.edu
-
San Diego, California, Vereinigte Staaten, 92103
- UCSD Antiviral Research Center (Site ID: 701)
-
Kontakt:
- Dawn Rosenblum
- Telefonnummer: 619-543-8080
- E-Mail: drosenblum@health.ucsd.edu
-
San Francisco, California, Vereinigte Staaten, 94110
- University of California, San Francisco (Site ID: 801)
-
Kontakt:
- Jay Dwyer
- Telefonnummer: 415-502-5748
- E-Mail: jay.dwyer@ucsf.edu
-
Torrance, California, Vereinigte Staaten, 90502-2052
- Harbor University of California Los Angeles Center (Site ID: 603)
-
Kontakt:
- Mario Guerrero
- Telefonnummer: 323-457-1459
- E-Mail: mguerrero@lundquist.org
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80045
- University of Colorado Hospital (Site ID: 6101)
-
Kontakt:
- Nicola Haakonsen
- Telefonnummer: 303-724-5931
- E-Mail: nicola.haakonsen@cuanschutz.edu
-
-
District of Columbia
-
Washington D.C., District of Columbia, Vereinigte Staaten, 20032
- Whitman-Walker Institute, Inc. (Site ID: 21791)
-
Kontakt:
- Avery Wimpelberg
- Telefonnummer: 202-797-3589
- E-Mail: awimpelberg@whitman-walker.org
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Northwestern University (Site ID: 2701)
-
Kontakt:
- Sherryl L Wolfe
- Telefonnummer: 312-695-4997
- E-Mail: s-wolfe@northwestern.edu
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21287
- Johns Hopkins University (Site ID: 201)
-
Kontakt:
- Rebecca L Becker
- Telefonnummer: 410-614-4036
- E-Mail: rbecke22@jhmi.edu
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Massachusetts General Hospital (Site ID: 101)
-
Kontakt:
- Amy Sbrolla
- Telefonnummer: 617-726-5598
- E-Mail: asbrolla@mgh.harvard.edu
-
Boston, Massachusetts, Vereinigte Staaten, 02115
- Brigham and Women's Hospital Therapeutics (BWH TCRS) (Site ID: 107)
-
Kontakt:
- Hannah Jordan
- Telefonnummer: 617-732-4785
- E-Mail: hcjordan@bwh.harvard.edu
-
-
New Jersey
-
Newark, New Jersey, Vereinigte Staaten, 07103
- New Jersey Medical School Clinical Research Center (Site ID: 31786)
-
Kontakt:
- Christie Lyn Costanza
- Telefonnummer: 972-972-9069
- E-Mail: costancl@njms.rutgers.edu
-
-
New York
-
New York, New York, Vereinigte Staaten, 10010
- Weill Cornell Chelsea (Site ID: 7804)
-
Kontakt:
- Mauricio Vergara
- Telefonnummer: 212-746-7204
- E-Mail: mav9177@med.cornell.edu
-
New York, New York, Vereinigte Staaten, 10010
- Weill Cornell Uptown (Site ID: 7803)
-
Kontakt:
- Keisha Ballentine-Cargill
- Telefonnummer: 212-746-7804
- E-Mail: keb4006@med.cornell.edu
-
New York, New York, Vereinigte Staaten, 10032
- Columbia Physicians & Surgeons (P&S) (Site ID: 30329)
-
Kontakt:
- Brett T Gray
- Telefonnummer: 212-305-1570
- E-Mail: bg2168@cumc.columbia.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27599-7215
- Chapel Hill (Site ID: 3201)
-
Kontakt:
- Erin Elizabeth Hoffman
- Telefonnummer: 919-843-0720
- E-Mail: erin_hoffman@med.unc.edu
-
Greensboro, North Carolina, Vereinigte Staaten, 27401-1020
- Greensboro (Site ID: 3203)
-
Kontakt:
- Kelly Phillips
- Telefonnummer: 336-832-7297
- E-Mail: kelly.phillips@conehealth.com
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 45267-0405
- Cincinnati Clinical Research Site (Site ID: 2401)
-
Kontakt:
- Michelle Saemann
- Telefonnummer: 513-584-2245
- E-Mail: saemanmd@ucmail.uc.edu
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- Case Clinical Research Site (Site ID: 2501)
-
Kontakt:
- Julie Pasternak
- Telefonnummer: 216-844-2738
- E-Mail: pasternak.julie@clevelandactu.org
-
Columbus, Ohio, Vereinigte Staaten, 43210
- Ohio State University (Site ID: 2301)
-
Kontakt:
- Lindsay Summers
- Telefonnummer: 614-293-8529
- E-Mail: lindsay.summers@osumc.edu
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15213
- University of Pittsburgh (Site ID: 1001)
-
Kontakt:
- Stacey Edick
- Telefonnummer: 412-383-1748
- E-Mail: edicksm2@upmc.edu
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37204
- Vanderbilt Therapeutics (VT) (Site ID: 3652)
-
Kontakt:
- Beverly Woodward
- Telefonnummer: 615-936-8516
- E-Mail: beverly.o.woodward@vumc.org
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77030
- Houston Advancing Research Team (Site ID: 31473)
-
Kontakt:
- Maria Laura Martinez
- Telefonnummer: 713-500-6718
- E-Mail: maria.l.martinez@uth.tmc.edu
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98104
- University of Washington Positive Research (Site ID: 1401)
-
Kontakt:
- Allysson Angeldekao
- Telefonnummer: 503-715-7324
- E-Mail: allysson@uw.edu
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Documented HIV-1 infection
-
Prior antiretroviral therapy (ART) experience, including having first been prescribed ART at least 24 weeks prior to enrollment and self-report of prior oral ART use
-
HIV-1 RNA >1000 copies/mL within 60 days prior to study entry
-
Evidence of non-adherence to ART, including virologic failure, poor virologic response, or loss to clinical follow-up with ART non-use/non-adherence
-
At least one reason why NNRTI-based ART is clinically inappropriate, including documented or suspected rilpivirine resistance or prior rilpivirine intolerance
-
Adequate laboratory parameters within 60 days prior to study entry:
- Absolute neutrophil count >600/mm3
- Hemoglobin ≥7.0 g/dL
- Platelet count >50,000/μL
- AST and ALT ≤3 × upper limit of normal
- Estimated glomerular filtration rate >15 mL/min/1.73 m²
-
For participants of childbearing potential, negative pregnancy test at screening and within 24 hours prior to study entry
-
Ability and willingness to provide informed consent
-
Connected to a medical clinic with access to HIV care and antiretroviral therapy
Exclusion Criteria:
- Documented integrase strand transfer inhibitor (INSTI) resistance-associated mutations that may compromise cabotegravir activity
- Active hepatitis B infection, defined as positive hepatitis B surface antigen or detectable hepatitis B virus DNA
- Child-Pugh Class C cirrhosis
- No suitable injection site for cabotegravir administration due to implants, tattoos, or skin conditions interfering with injection site assessment
- Prior use of lenacapavir
- Receipt of HIV immunotherapeutic vaccines or HIV monoclonal antibodies within 6 months prior to study entry
- Serious medical or psychiatric condition
- Use of prohibited concomitant medications with lenacapavir or cabotegravir within 30 days prior to study entry
- Current pregnancy or breastfeeding
- Known allergy, hypersensitivity, or intolerance to cabotegravir, lenacapavir, or formulation components
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Long-Acting Lenacapavir Plus Long-Acting Cabotegravir
|
Long-acting subcutaneous lenacapavir administered every 24 weeks with oral loading doses at treatment initiation. Long-acting intramuscular cabotegravir administered every 8 weeks following initiation doses. Oral antiretroviral therapy provided as bridge therapy during interruptions or delays in long-acting treatment. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Proportion of participants achieving and maintaining viral suppression (no confirmed virologic failure) while receiving long-acting lenacapavir plus cabotegravir
Zeitfenster: Baseline through Week 48
|
Baseline through Week 48
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Zeitfenster: Week 48
|
Week 48
|
|
|
Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Zeitfenster: Week 48
|
Week 48
|
|
|
Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Zeitfenster: Week 48
|
Week 48
|
|
|
Proportion of participants with Grade 3 or higher adverse events related to long-acting lenacapavir plus cabotegravir
Zeitfenster: Baseline through Week 96
|
Baseline through Week 96
|
|
|
Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir due to adverse events or intolerance
Zeitfenster: Baseline through Week 96
|
Baseline through Week 96
|
|
|
Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure on long-acting lenacapavir plus cabotegravir
Zeitfenster: Baseline through Week 96
|
Baseline through Week 96
|
|
|
Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Zeitfenster: Week 96
|
Week 96
|
|
|
Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Zeitfenster: Week 96
|
Week 96
|
|
|
Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Zeitfenster: Week 96
|
Week 96
|
|
|
Percentage of on-time long-acting injections
Zeitfenster: Through Week 48 and through Week 96
|
Through Week 48 and through Week 96
|
|
|
Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir
Zeitfenster: Baseline through Week 48 and through Week 96
|
Baseline through Week 48 and through Week 96
|
|
|
Plasma trough concentrations of lenacapavir and cabotegravir
Zeitfenster: Through Week 48 and through Week 96
|
Through Week 48 and through Week 96
|
|
|
Change in CD4 cell count from baseline
Zeitfenster: Week 48 and Week 96
|
Week 48 and Week 96
|
|
|
Participant-reported treatment satisfaction
Zeitfenster: Week 48 and Week 96
|
HIV Treatment Satisfaction Questionnaire assesses participant satisfaction with the long-acting treatment. |
Week 48 and Week 96
|
|
Change in quality-of-life scores from baseline
Zeitfenster: Week 48 and Week 96
|
Quality of life will be assessed using the Veterans Rand 12-item Health Survey (VR-12). Scores range from 0 to 100, with higher scores indicating better health-related quality of life. |
Week 48 and Week 96
|
|
Change in Patient Health Questionnaire-9 (PHQ-9) scores from baseline
Zeitfenster: Week 48 and Week 96
|
Symptoms will be assessed using the Patient Health Questionnaire-9 (PHQ-9). Scores range from 0 to 27, with higher scores indicating more severe depressive symptoms. |
Week 48 and Week 96
|
|
Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure among participants not requiring oral bridge therapy
Zeitfenster: Baseline through Week 48
|
Baseline through Week 48
|
|
|
Proportion of participants without oral bridge therapy with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Zeitfenster: Week 48
|
Week 48
|
|
|
Proportion of participants without oral bridge therapy with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Zeitfenster: Week 48
|
Week 48
|
|
|
Proportion of participants without oral bridge therapy with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Zeitfenster: Week 48
|
Week 48
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- A5431
- 39159 (Andere Kennung: DAIDS-ES ID)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Individual participant data that underlie results in the publication after deidentification
IPD-Sharing-Zeitrahmen
Beginning 3 months following publication and available throughout period of funding of the Advancing Clinical Therapeutics Globally (ACTG) by NIH
IPD-Sharing-Zugriffskriterien
With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the ACTG.
For what types of analyses? To achieve aims in the proposal approved by the ACTG.
By what mechanism will data be made available? Researchers may submit a request for access to data using the ACTG "Data Request" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an ACTG Data Use Agreement before receiving the data
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .